MTF Biologics has expanded its reconstructive surgery portfolio with FlexHD® Meshed, a pre-meshed acellular dermal allograft developed in collaboration with surgeons to deliver fast, flexible, coverage for complex soft tissue defects in surgical procedures.
EDISON, N.J., June 4, 2026 -(BUSINESS WIRE)- MTF Biologics, a global nonprofit organization that saves and heals lives by honoring donated gifts, serving patients, and advancing the science of tissue transplantation, today announced the launch of FlexHD® Meshed, an extension of its FlexHD® portfolio. Developed to meet the complex needs of reconstructive surgery, the pre-meshed configuration is optimized for use in soft tissue defects by addressing irregular wound geometries and accelerating coverage for efficient graft incorporation.
“FlexHD® has long been a trusted resource for plastic surgeons across a wide spectrum of reconstructive needs, and we’re pleased to extend that trusted performance into a clinically distinct space. FlexHD® Meshed was developed alongside the surgeons who face these cases daily – where wound geometry is unforgiving, time in the operating room is precious, and the patient has already been through enough. When the stakes are high, the tools shouldn’t add to the burden. That’s what FlexHD® has always stood for, and it’s precisely why MTF Biologics exists,” said Brian Leuthner, Vice President & General Manager of the Soft Tissue, Aesthetics, and Reconstruction franchise.
FlexHD® acellular dermis matrices (ADMs) are cut from a deeper layer of dermis and aseptically processed to ensure superior handling, clinical efficacy, and the highest level of sterility assurance. FlexHD® Meshed delivers these attributes and the trusted FlexHD® performance in a convenient, ready-to-use configuration. The allograft provides a structural scaffold that supports cellular repopulation and tissue integration, facilitating the reconstructive pathway for surgeons treating deep tissue injuries and complex wounds.
By eliminating the need for intraoperative preparation, the pre-meshed allograft significantly reduces time in the operating room. It was also developed to address the unique challenges of deep tissue injuries and complex soft tissue defects, providing immediate, deployable coverage that conforms readily to irregular anatomy and expands surface area coverage while promoting optimal fluid drainage. FlexHD® Meshed is now available through MTF Biologics. For more information on MTF Biologics and its growing line of reconstructive tissue solutions, please visit www.mtfbiologics.org.
About MTF Biologics
MTF Biologics is a global nonprofit organization that saves and heals lives by honoring donated gifts, serving patients, and advancing science. In partnership with organ and tissue recovery organizations, MTF Biologics provides exceptional services, resources, and expertise to donors and their families; tissue and organ transplant patients; and clinicians and scientists who advance patient care.
The International Institute for the Advancement of Medicine (IIAM), a Division of MTF Biologics, honors donors of non-transplantable organs by providing their gifts to the medical research community to combat and cure diseases. Statline, also a Division of MTF Biologics, provides specialized screening, coordination, and communications services to organ transplant centers, organ, tissue, and eye procurement organizations, and the hospitals and patients that they serve. Its sister organization, Deutsches Institut für Zell- und Gewebeersatz – DIZG (The German Institute for Cell and Tissue Transplantation) expands its reach to patients across the globe.
Contacts
Aleksa Alden
Email: aleksa.alden@finnpartners.com
